TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00908817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: paste applied over tracheal tube for lubrication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chlorhexidine gluconate
Description: jelly applied over tracheal tube for lubrication
Study: NCT01901276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg bid
Description: As above.
Study: NCT00492791

Intervention type: DEVICE
Intervention: wireless endoscopy capsule
Description: Firslty patency ingestion then wireless endoscopy capsule exam done
Study: NCT03753841

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment of oral diet
Description: Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
Study: NCT00662480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm
Description: Invited to vascular screening
Study: NCT04302844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imago Relationship Therapy
Description: Imago relationship therapy (IRT) involves learning the Imago dialogue process, which helps couples understand more clearly why they and their partners react as they do. Couples practice communicating in a manner that helps them move from reactivity and blame to understanding and empathy. The dialogue is used to transform conflicts into opportunities for healing and growth, and to connect more deeply and effectively with one another. Specific topics of therapy are determined by the couple's needs and goals. In general, the therapist helps them use the Imago dialogue to promote understanding, heal painful emotions, and make requests of one another to change behaviors. In effort to minimize risk of exposure to the virus that causes COVID-19, since the spring of 2020, therapy sessions will be conducted via telehealth, with a HIPAA-compliant audio/visual platform, and with couples at home or in another private place during the therapy sessions and the therapist in his or her office.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist with Bibliotherapy followed by Workshop
Description: Participants assigned to this group will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read, with exercises to practice, during that time. After 12 weeks and the 12-week assessment has been completed, couples will attend an educational workshop that provides the principles and communication skills of Imago Relationship Therapy, typically in a weekend format that is usually about 18-20 hours. The workshops, called Getting the Love You Want (GTLYW), are led by certified and experienced Imago workshop presenters, and are attended by a group of couples. The workshop includes presentations, discussions, and practice of communication exercises. Participation in the workshops will also be virtual or via telehealth, as described above.
Study: NCT01714193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Description: One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
Study: NCT00355940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Methods
Description: Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Fluoroscopy
Description: Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
Study: NCT02994719

Intervention type: DRUG
Intervention: Anti-Parkinson medication
Description: During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
Study: NCT03257813

Intervention type: DRUG
Group type: OTHER
Intervention: PRO-122
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days

Intervention type: DRUG
Group type: OTHER
Intervention: PRO-122
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days

Intervention type: DRUG
Group type: OTHER
Intervention: Krytantek Ofteno®
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days

Intervention type: DRUG
Group type: OTHER
Intervention: Krytantek Ofteno®
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days
Study: NCT02562391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ablation of the left atrium (PVI+Box lesions)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting
Study: NCT01305291

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: digestion-resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: digestion-resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: digestion-resistant maltodextrin
Study: NCT02683811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diario della Salute (DDS-2)
Description: The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
Study: NCT02602743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanyl
Description: 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 2 mg/kg ketamine will be administered for induction in 1 minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 2 mg/kg ketamine will be administered for induction in 1 minute.
Study: NCT00801983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternative Keyboard
Description: Subjects use either a typical or alternative keyboard

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternative Keyboard
Description: Subjects use either a typical or alternative keyboard
Study: NCT01424540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 150mg
Description: Single Dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose
Study: NCT02910388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLETZ with colposcopy
Description: Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ without colposcopy
Description: Loop procedure without using a colposcope
Study: NCT00676234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetinum
Description: Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
Study: NCT03522467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRCP001
Description: MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
Study: NCT03103295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3D-Tissue Engineered Bone Equivalent
Description: Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
Study: NCT04617652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
Study: NCT04033042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.5
Description: Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.5
Description: Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
Study: NCT02765438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BOBO
Description: Each subject will play four games with the BOBO system.
Study: NCT01883908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture with Seirin® needles
Description: Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual medical care
Description: usual medical care such as viscous Lidocaine for relief of pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Description: usual medical care such as viscous Lidocaine for relief of pain
Study: NCT02778958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
Study: NCT04567407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral erector spinae blocks using ropivacaine
Description: Bilateral chest wall nerve blocks using ropivacaine.
Study: NCT02342119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talking About Living Kidney Donation
Description: TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kidney Transplant Fast Track
Description: KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney Transplant Fast Track
Description: KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
Study: NCT04153435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Chloride
Description: Calcium chloride 5 mmol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Placebo
Study: NCT00864786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled doses of 200 mcgQD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled doses of 600 mcg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled doses of 1000 mcg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
Study: NCT04052971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABN401- Escalation Phase
Description: Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 50 mg to 1800 mg QD daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABN401- Expansion Phase
Description: Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal.
Study: NCT00864786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
Study: NCT01885806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Stimulator Magstim Rapid 2
Description: All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Magnetic Stimulator
Description: This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10
Study: NCT00867191

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 tablet daily, per os., 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine, one 5 mg tablet daily, per os, 15 days
Study: NCT01259258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without dye varicocelectomy
Description: 40 controls in whom no mapping technique was adopted in the period between

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without dye varicocelectomy
Description: 40 controls in whom no mapping technique was adopted in the period between
Study: NCT03279952

Intervention type: DRUG
Group type: OTHER
Intervention: CNS Stimulant
Description: Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
Study: NCT01276626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum
Description: Powder containing Bifidobacterium longum in maltodextrin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Powder containing only maltodextrin
Study: NCT03047135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
Study: NCT00918619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sangustop
Description: Application of Sangustop haemostatic agent on resection area
Study: NCT03763175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN-010 21 mg
Description: 21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN-010 42 mg
Description: 42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
Study: NCT02846480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgical treatment
Description: Surgical correction of POP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgical treatment
Description: Surgical correction of POP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavior therapy
Description: At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavior therapy
Description: At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
Study: NCT03368937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology
Description: Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
Study: NCT01271452

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
Study: NCT00918619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tachosil
Description: Application of Tachosil fibrin sealant on resection area
Study: NCT01271452

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
Study: NCT03614546

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity-modulated Radiation Therapy (IMRT)
Study: NCT00153660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib(drug)
Description: Celecoxib 100 mg bd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen(drug)
Description: Naproxen 500 mg bd
Study: NCT01736917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5HT3
Description: Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.